Hair Care and Hair Styling Products | Biolage Professional
Biolage is recognized worldwide as a leader in the professional hair care field, and that reputation continues to grow. We believe this is because Biolage is constantly improving—taking hair …
Home | Biogen
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases.
Biogen - Wikipedia
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of the treatment of neurological diseases to patients worldwide.
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives …
1 天前 · CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the ...
Company | Biogen
2015年3月25日 · Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities.
关于渤健中国 | Biogen
渤健于2017年在中国注册成立，之后在中国上市首个用于脊髓性肌萎缩症治疗的药物、及两款治疗多发性硬化的创新药物。
Biogen’s Investigational Tau-Targeting Therapy BIIB080
1 天前 · MEDIA CONTACT: Biogen Jack Cox + 1 781 464 3260 [email protected]: INVESTOR CONTACT: Biogen Tim Power +1 781 464 2442 [email protected]
Update on Regulatory Review of Lecanemab for Early Alzheimer’s …
2 天之前 · TOKYO and CAMBRIDGE, Mass., April 1, 2025 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as a treatment for early AD (mild ...
FDA Grants Fast Track Designation to Biogen’s Novel Alzheimer …
1 天前 · The FDA has granted Fast Track designation to Biogen’s BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau for the treatment of Alzheimer disease (AD). In a press release, Biogen noted that BIIB080 is the first ASO targeting tau to enter clinical development. It is ...
Biogen Announces Plans for New Global Headquarters and …
2025年3月24日 · MEDIA CONTACT: Biogen Jack Cox +1 781 464 3260 [email protected]: INVESTOR CONTACT: Biogen Tim Power +1 781 464 2442 …